These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

282 related articles for article (PubMed ID: 26307900)

  • 1. SGLT-2 INHIBITOR THERAPY ADDED TO GLP-1 AGONIST THERAPY IN THE MANAGEMENT OF T2DM.
    Saroka RM; Kane MP; Busch RS; Watsky J; Hamilton RA
    Endocr Pract; 2015 Dec; 21(12):1315-22. PubMed ID: 26307900
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Quality goal attainment and maintenance in patients with type II diabetes mellitus initiated on canagliflozin or a glucagon-like peptide-1 receptor agonist in an actual practice setting.
    Wysham CH; Pilon D; Ingham M; Lafeuille MH; Emond B; Kamstra R; Pfeifer M; Lefebvre P
    Curr Med Res Opin; 2018 Jun; 34(6):1125-1133. PubMed ID: 29557199
    [TBL] [Abstract][Full Text] [Related]  

  • 3. HBA1C CONTROL AND COST-EFFECTIVENESS IN PATIENTS WITH TYPE 2 DIABETES MELLITUS INITIATED ON CANAGLIFLOZIN OR A GLUCAGON-LIKE PEPTIDE 1 RECEPTOR AGONIST IN A REAL-WORLD SETTING.
    Wysham CH; Pilon D; Ingham M; Lafeuille MH; Emond B; Kamstra R; Pfeifer M; Lefebvre P
    Endocr Pract; 2018 Mar; 24(3):273-287. PubMed ID: 29547044
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy and safety of canagliflozin as add-on therapy to a glucagon-like peptide-1 receptor agonist in Japanese patients with type 2 diabetes mellitus: A 52-week, open-label, phase IV study.
    Harashima SI; Inagaki N; Kondo K; Maruyama N; Otsuka M; Kawaguchi Y; Watanabe Y
    Diabetes Obes Metab; 2018 Jul; 20(7):1770-1775. PubMed ID: 29473709
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effects of canagliflozin, an SGLT2 inhibitor, on hepatic function in Japanese patients with type 2 diabetes mellitus: pooled and subgroup analyses of clinical trials.
    Seko Y; Sumida Y; Sasaki K; Itoh Y; Iijima H; Hashimoto T; Ishii S; Inagaki N
    J Gastroenterol; 2018 Jan; 53(1):140-151. PubMed ID: 28669071
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy and safety of once-weekly semaglutide versus daily canagliflozin as add-on to metformin in patients with type 2 diabetes (SUSTAIN 8): a double-blind, phase 3b, randomised controlled trial.
    Lingvay I; Catarig AM; Frias JP; Kumar H; Lausvig NL; le Roux CW; Thielke D; Viljoen A; McCrimmon RJ
    Lancet Diabetes Endocrinol; 2019 Nov; 7(11):834-844. PubMed ID: 31540867
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy and safety of canagliflozin as add-on therapy to teneligliptin in Japanese patients with type 2 diabetes mellitus: Results of a 24-week, randomized, double-blind, placebo-controlled trial.
    Kadowaki T; Inagaki N; Kondo K; Nishimura K; Kaneko G; Maruyama N; Nakanishi N; Iijima H; Watanabe Y; Gouda M
    Diabetes Obes Metab; 2017 Jun; 19(6):874-882. PubMed ID: 28177187
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effectiveness, treatment durability, and treatment costs of canagliflozin and glucagon-like peptide-1 receptor agonists in patients with type 2 diabetes in the USA.
    Singhal M; Tan H; Coleman CI; Han M; Nguyen C; Ingham M
    BMJ Open Diabetes Res Care; 2019; 7(1):e000704. PubMed ID: 31798890
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Canagliflozin in Conjunction With Sulfonylurea Maintains Glycemic Control and Weight Loss Over 52 Weeks: A Randomized, Controlled Trial in Patients With Type 2 Diabetes Mellitus.
    Yale JF; Xie J; Sherman SE; Garceau C
    Clin Ther; 2017 Nov; 39(11):2230-2242.e2. PubMed ID: 29103664
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The efficacy and safety of canagliflozin across racial groups in patients with type 2 diabetes mellitus.
    Gavin JR; Davies MJ; Davies M; Vijapurkar U; Alba M; Meininger G
    Curr Med Res Opin; 2015; 31(9):1693-702. PubMed ID: 26121561
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A Comparative Study of efficacy and safety of different Sodium Glucose Co-transporter 2 (SGLT-2) Inhibitors in the Management of Patients with Type II Diabetes Mellitus.
    Bhosle D; Indurkar S; Quadri U; Chandekar B
    J Assoc Physicians India; 2022 Jun; 70(6):11-12. PubMed ID: 35702841
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy and safety of canagliflozin when used in conjunction with incretin-mimetic therapy in patients with type 2 diabetes.
    Fulcher G; Matthews DR; Perkovic V; de Zeeuw D; Mahaffey KW; Mathieu C; Woo V; Wysham C; Capuano G; Desai M; Shaw W; Vercruysse F; Meininger G; Neal B;
    Diabetes Obes Metab; 2016 Jan; 18(1):82-91. PubMed ID: 26450639
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prandial insulin versus glucagon-like peptide-1 added to basal insulin: comparative effectiveness in the community practice setting.
    Digenio A; Karve S; Candrilli SD; Dalal M
    Postgrad Med; 2014 Oct; 126(6):49-59. PubMed ID: 25414934
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Long-Term Effectiveness and Safety of SGLT-2 Inhibitors in an Italian Cohort of Patients with Type 2 Diabetes Mellitus.
    Mirabelli M; Chiefari E; Caroleo P; Vero R; Brunetti FS; Corigliano DM; Arcidiacono B; Foti DP; Puccio L; Brunetti A
    J Diabetes Res; 2019; 2019():3971060. PubMed ID: 31781664
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Real world study of short term efficacy, safety, and tolerability of canagliflozin 100 mg initiation in type 2 diabetes mellitus patients during hot humid Indian summer.
    Sanyal D; Majumder A; Ghosh S; Pandit K
    Diabetes Metab Syndr; 2021; 15(1):385-389. PubMed ID: 33548908
    [TBL] [Abstract][Full Text] [Related]  

  • 16. SGLT-2 INHIBITION ADDED TO GLP-1 AGONIST THERAPY FOR TYPE 2 DIABETES: WHAT IS THE BENEFIT?
    Bloomgarden ZT; Handelsman Y
    Endocr Pract; 2015 Dec; 21(12):1442-4. PubMed ID: 26484408
    [No Abstract]   [Full Text] [Related]  

  • 17. Spotlight on Canagliflozin 300: review of its efficacy and an indirect comparison to other SGLT-2 inhibitors and long-acting GLP-1 receptor agonists.
    Singh AK; Singh R
    Expert Rev Clin Pharmacol; 2017 Jun; 10(6):633-647. PubMed ID: 28393583
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Canagliflozin provides greater attainment of both HbA1c and body weight reduction versus sitagliptin in patients with type 2 diabetes.
    Schernthaner G; Lavalle-González FJ; Davidson JA; Jodon H; Vijapurkar U; Qiu R; Canovatchel W
    Postgrad Med; 2016 Nov; 128(8):725-730. PubMed ID: 27391951
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Combination Therapy With Canagliflozin Plus Liraglutide Exerts Additive Effect on Weight Loss, but Not on HbA
    Ali AM; Martinez R; Al-Jobori H; Adams J; Triplitt C; DeFronzo R; Cersosimo E; Abdul-Ghani M
    Diabetes Care; 2020 Jun; 43(6):1234-1241. PubMed ID: 32220916
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Real-world Clinical Outcomes Among Patients With Type 2 Diabetes Receiving Canagliflozin at a Specialty Diabetes Clinic: Subgroup Analysis by Baseline HbA
    Johnson JF; Parsa R; Bailey RA
    Clin Ther; 2017 Jun; 39(6):1123-1131. PubMed ID: 28495028
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.